Aligos Therapeutics, Inc. (ALGS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Aligos Therapeutics, Inc. reported revenue of $2.19M, down 39.5% from the prior year. The company ran a net loss, with a net margin of -1106.7%. It held $88.53M in total assets against $34.99M in total liabilities.
Key ratios (FY2025)
-4024.9%
Operating margin
-1106.7%
Net margin
-45.2%
Return on equity
-39.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.19M | $3.61M | $6.19M | $0 | $0 | $0 | — | — |
| Operating Income | -$87.98M | -$89.15M | -$88.13M | -$97.58M | -$128.32M | -$97.83M | -$54.04M | — |
| Net Income | -$24.19M | -$131.21M | -$87.68M | -$96.05M | -$128.33M | -$108.54M | -$52.26M | — |
| EPS (Diluted) | $-2.45 | $-20.94 | $-34.20 | $-2.25 | — | — | — | — |
| Total Assets | $88.53M | $70.09M | $151.53M | $146.69M | $235.37M | $265.30M | $146.52M | — |
| Total Liabilities | $34.99M | $99.07M | $59.45M | $42.79M | $50.64M | $45.26M | $29.33M | — |
| Shareholders' Equity | $53.55M | -$28.97M | $92.08M | $103.90M | $184.73M | $220.04M | -$64.89M | -$13.75M |
| Cash & Equivalents | $18.30M | $37.00M | $135.70M | $81.35M | $186.82M | $220.38M | $69.56M | — |
| Operating Cash Flow | -$82.50M | -$80.74M | -$79.00M | -$79.39M | -$115.66M | -$74.26M | -$46.77M | — |
| Capital Expenditures | — | $130.0K | $19.0K | $943.0K | $892.0K | $2.06M | $2.79M | — |
| Shares Outstanding | 6.18M | 3.86M | 3.00M | 42.92M | 42.69M | 38.12M | 3.93M | — |